Loading next page...
/lp/american-medical-association/clinical-and-serologic-responses-to-acellular-pertussis-vaccine-in-QjEkRpqLYX
- Publisher
- American Medical Association
- Copyright
- Copyright © 1987 American Medical Association. All Rights Reserved.
- ISSN
- 0002-922X
- DOI
- 10.1001/archpedi.1987.04460090026016
- Publisher site
- See Article on Publisher Site
Abstract
Abstract • We administered diphtheria, tetanus, and pertussis (DTP) vaccine containing acellular (lymphocytosis promoting factor and filamentous hemagglutinin) pertussis vaccine to three groups of 20 children each (4 to 6 years, 17 to 21 months, and 5 to 9 months of age). All the children tolerated the vaccine well; no reactions occurred that contraindicated further Immunization. Older children had significantly more local (redness or swelling) and systemic (fever or fretfulness) reactions than younger children. Eighty percent to 90% of the children in the two older age groups had fourfold or greater increases in antibody titers to DTP antigens one month after vaccination. The postvaccine concentrations of antibody to tetanus and diphtheria were greater than 0.01 IU/mL In all children. Serologic responses to lymphocytosis promoting and filamentous hemagglutinin varied with age; significantly more older children than younger children had four-fold or greater increases. Acellular pertussis DTP vaccine was antigenic in young children and was less reactogenic than standard whole cell DTP vaccine according to rates reported in previous studies. (AJDC 1987;141:949-953) References 1. Broome CV, Fraser DW: Pertussis in the United States, 1979: A look at vaccine efficacy . J Infect Dis 1981;144:187-190.Crossref 2. Pertussis: Maryland, 1982 . MMWR 1983; 32:297-300. 3. Pertussis: Washington, 1984 . MMWR 1985;34:390-399. 4. Pertussis: United States, 1982 and 1983 . MMWR 1984;33:573-575. 5. Pertussis surveillance, 1979-1981 . MMWR 1982;31:333-336. 6. Pertussis outbreak: Oklahoma . MMWR 1984;33:2-10. 7. Hinman AR, Koplan JP: Pertussis and pertussis vaccine: Reanalysis of benefits, risks and costs . JAMA 1984;251:3109-3113.Crossref 8. Schoenbaum SC, Weinstein MC, et al: Pertussis vaccine: An analysis of benefits, risks, and costs . N Engl J Med 1979;301:906-911.Crossref 9. Miller DL, Alderslade R, Ross EM: Whooping cough and whooping cough vaccine: The risks and benefits debate . Epidemiol Rev 1982;4:1-24. 10. Cody CL, Baraff LJ, Cherry JD, et al: Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and Pediatrics 1981;68:650-660. 11. Sato Y, Kimura M, Fukumi H: Development of a pertussis component vaccine in Japan . Lancet 1984;1:122-126.Crossref 12. Aoyama T, Murase Y, Kato T, et al: Efficacy of an acellular pertussis vaccine in Japan . J Pediatr 1985;107:180-183.Crossref 13. Edwards KM, Lawrence E, Wright PF: Diphtheria, tetanus, and pertussis vaccine: A comparison of the immune response and adverse reactions to conventional and acellular pertussis components . AJDC 1986;140:867-876. 14. Lewis K, Cherry JC, Holroyd J, et al: A double-blind study comparing an acellular pertussis–component DTP vaccine with a whole-cell pertussis–component DTP vaccine in 18-month-old children . AJDC 1986;140:872-876. 15. Pittman M: The concept of pertussis as a toxin mediated disease . Pediatr Infect Dis 1984;3:467-486.Crossref 16. Tuomanen El, Weiss A: Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory epithelial cells . J Infect Dis 1985;152:118-125.Crossref 17. Oda M, Cowell JL, Burstyn DG, et al: Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice . J Infect Dis 1984;150:823-833.Crossref 18. Munoz JJ, Arai H, Cole RL: Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis . Infect Immun 1981;32: 243-250. 19. Oda M, Izumiya K, Sato Y, et al: Transplacental and transcolostral immunity to pertussis in a mouse model using acellular pertussis vaccine . J Infect Dis 1983;148:138-145.Crossref 20. Tuomanen El, Hendley JO: Adherence of Bordetella pertussis to human respiratory epithelial cells . J Infect Dis 1983;148:125-130.Crossref 21. Manclark CR, Meade BD: Serological response to Bordetella pertussis , in Rose NR, Friedman H (eds): Manual of Clinical Immunology , ed 2. Washington, DC, American Society for Microbiology, 1980, pp 496-499. 22. Millian SJ, Cherubin CE, Sherwin R, et al: A serologic survey of tetanus and diphtheria immunity in New York City . Arch Environ Health 1967;15:776-781.Crossref 23. Miyamura K, Nishio S, Ito A, et al: Microcell culture method for determination of diphtheria toxin and antitoxin titers using Vero cells: I. Studies on factors affecting the toxin and antitoxin titration . J Biol Stand 1974;2:189-201.Crossref 24. McComb JA, Dwyer RC: Passive-active immunization with tetanus immune globulin (human) . N Engl J Med 1963;268:857-862.Crossref 25. Vernon SK, Wiener P, Urbano C, et al: An antigen-conserving ELISA for detecting human antibodies to Bordetella pertussis filamentous hemagglutinin . J Biol Stand 1986;14:157-161.Crossref 26. Daniel W: Biostatistics: A Foundation for Analysis in the Health Sciences . New York, John Wiley & Sons Inc, 1974, pp 346-351. 27. Barkin RM, Samuelson JS, Gotlin LP: DTP reactions and serologic response with a reduced dose schedule . J Pediatr 1984;105: 189-194.Crossref 28. Barkin RM, Pichichero ME: Diphtheria-pertussis-tetanus vaccine: Reactogenicity of commercial products . Pediatrics 1979;63: 256-260. 29. Crossley K, Irvine P, Warren JB, et al: Tetanus and diphtheria immunity in urban Minnesota adults . JAMA 1979;242:2298-2300.Crossref
Journal
American Journal of Diseases of Children – American Medical Association
Published: Sep 1, 1987
@Phil_Robichaud
@deepthiw
@JoseServera